Ocugen, Inc. Share Price & Technical Analysis
OCGN · $1.34 (-0.74%)
Healthcare / Biotechnology
$1.34
-0.74%
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-24% return in May, 5% avg return in past 3 year May month.
4% return in 2026, 34% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | 20% | 6% | -6% | -24% | – | – | – | – | – | – | – | 4% |
| 25 | -22% | 0% | 0% | 0% | 14% | 25% | 0% | 0% | 60% | 0% | -25% | 17% | 69% |
| 24 | -17% | 80% | 78% | -19% | 31% | -12% | -7% | 0% | -23% | -10% | 11% | -20% | 93% |
| 23 | 0% | -17% | -10% | -22% | -29% | 0% | 0% | -33% | 0% | 0% | 0% | 50% | -61% |
| 22 | -24% | 0% | -6% | -33% | 9% | -4% | 13% | 4% | -28% | -6% | -11% | -13% | -99% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$489.16M
P/E ratio
—
52W high
$2.73
52W low
$0.80
Volume
39,36,042
Beta
2.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ocugen, Inc. share price today?
- Ocugen, Inc. (OCGN) last traded around $1.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OCGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OCGN. Download the app for real-time alerts.
- How can I analyze Ocugen, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.